deferoxamine has been researched along with Hearing Loss, High-Frequency in 2 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hearing Loss, High-Frequency: Hearing loss in frequencies above 1000 hertz.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the frequency of eye and auditory complications and their relationship to drug dosage and iron stores in patients receiving deferoxamine, we studied 52 regularly transfused patients who received deferoxamine by subcutaneous or intravenous infusion in doses from 26 to 136 mg/kg/day, and whose serum ferritin levels of 185 to 17,775 micrograms/L reflected a wide range of iron stores." | 1.28 | Vision and hearing during deferoxamine therapy. ( Cohen, A; Konkle, DF; Martin, M; Mizanin, J; Schwartz, E, 1990) |
| "When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic." | 1.27 | Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. ( Boyden, MH; Carley, H; Freedman, MH; Gallant, LA; Gallant, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, A | 1 |
| Martin, M | 1 |
| Mizanin, J | 1 |
| Konkle, DF | 1 |
| Schwartz, E | 1 |
| Gallant, T | 1 |
| Boyden, MH | 1 |
| Gallant, LA | 1 |
| Carley, H | 1 |
| Freedman, MH | 1 |
2 other studies available for deferoxamine and Hearing Loss, High-Frequency
| Article | Year |
|---|---|
Vision and hearing during deferoxamine therapy.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Chelation Therapy; Child; Deferoxamine; Ferritins; Hearing L | 1990 |
Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
Topics: Adolescent; Adult; Audiometry; Child; Child, Preschool; Deferoxamine; Hearing Loss; Hearing Loss, Hi | 1987 |